Wall Street Weekahead: Gap between vaccine hopes and pandemic reality
poses market hazard
Send a link to a friend
[November 21, 2020]
By April Joyner
NEW YORK (Reuters) - As winter approaches,
U.S. equity investors are weighing brightening prospects for a COVID-19
vaccine against a resurgence of the pandemic across the United States.
Several market strategists have predicted significant gains in U.S.
stocks in 2021, as long as Congress passes further fiscal stimulus and a
vaccine becomes widely available in the first half. But the path for
stocks could be bumpy while investors await those developments, they
said.
Over the past few weeks, investors had largely looked past immediate
risks from the pandemic. The benchmark S&P 500 index recently soared to
record highs on evidence of high efficacy rates in two experimental
vaccines - from Moderna Inc and jointly from Pfizer Inc and BioNTech SE.
Both vaccines could be ready for U.S. authorization and distribution
within weeks, Health and Human Services Secretary Alex Azar has said.
Still, the pandemic remained an immediate threat as the number of U.S.
deaths from the disease has climbed to 250,000. The S&P 500 fell more
than 1% on Wednesday as New York City announced the closure of public
schools.
Economic indicators including a rise in jobless claims last week
signaled that the recovery may have stalled, reflecting the need for
further fiscal stimulus, some investors said. Data from IHS Markit's
flash purchasing managers' index and the Conference Board's consumer
confidence survey are scheduled for release next week.
"We anticipate a vaccine becoming partially available this year, but
that still leaves a gap," said Colin Moore, global chief investment
officer at Columbia Threadneedle Investments.
Further signs the pandemic is growing more severe could stir volatility
in U.S. stocks. The Cboe Volatility Index, known as Wall Street's "fear
gauge," fell sharply after the U.S. presidential election but has
leveled off and remains above its long-term average near 20. VIX futures
also reflect elevated expectations for market gyrations throughout the
first half of 2021.
Questions about more stimulus have fed volatility expectations,
investors said. Two U.S. Senate runoff elections in Georgia scheduled
for January could decide which political party controls that chamber and
hence the scope of further pandemic relief.
[to top of second column]
|
A street sign for Wall Street is seen outside the New York Stock
Exchange (NYSE) in Manhattan, New York City, U.S. December 28, 2016.
REUTERS/Andrew Kelly
"The big event risk in 2021 might be that's just completely off the
table," said Derek Devens, senior portfolio manager of Neuberger
Berman's options group, referring to further stimulus. "That would
be a pretty negative event for the market."
Some strategists anticipate a bid to haven currencies as a hedge
against market declines. TD Securities strategists wrote on Tuesday
that they expect the dollar, which has weakened this month, to gain
for a brief period in part due to "evolving COVID realities."
Societe Generale has recommended options strategies that would
benefit from a strengthening in the yen.
But overall, investors largely expect any further slide in U.S.
stocks to be fleeting. Restrictions on mobility and economic
activity in response to rising COVID-19 cases are likely to be more
limited than in the spring, they said. New York City, for instance,
has kept stores and restaurants open even as schools close.
Simply seeing a light at the end of the tunnel has helped limit
investor anxiety, said David Lefkowitz, head of Americas equities at
UBS Global Wealth Management. Even if a stimulus package does not
materialize as expected, optimism about a vaccine could blunt any
hit to U.S. stocks, in his view.
"There's a pretty clear line of sight to an improvement beginning
after the first quarter," he said. "I don't think we're going to see
a huge pullback because the market knows that this is a very
temporary situation."
(Reporting by April Joyner; Editing by David Gregorio)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |